StockMacro
Menu

NovoCure

$10.71 -41% in 6 monthsMarket cap $1.3B

NVCR on XNAS, Health Care, NovoCure Limited, job postings

Measures activity, not value. Not investment advice.

Shares fell 31% in a month even as quarterly revenue rose 16% to $193.4M.

  • BadNet loss of $121.7M over 12 months, operating margin at -17%
  • GoodInstitutional holders rose 13% to 239 from 212 the quarter before

Written by AI from the data on this page, 22 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.

Industry
Surgical & medical instruments & apparatus (Health Care)
Employees
1,605
Website
novocure.com
Listed
Nasdaq, US
Last results
29 Oct 2026
Next results
expected around 11 Jan 2027 (an estimate: a year ago it reported on 12 Jan 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $193.4M, net loss $10.4M.
Quarter to 31 Dec 2021: revenue $133.2M, net income -$26.5MQuarter to 31 Dec 2021: revenue $133.2M, net income -$26.5MQuarter to 31 Mar 2022: revenue $137.5M, net income -$4.6MQuarter to 31 Mar 2022: revenue $137.5M, net income -$4.6MQuarter to 30 Jun 2022: revenue $140.9M, net income -$24.0MQuarter to 30 Jun 2022: revenue $140.9M, net income -$24.0MQuarter to 30 Sep 2022: revenue $131.0M, net income -$26.6MQuarter to 30 Sep 2022: revenue $131.0M, net income -$26.6MQuarter to 31 Dec 2022: revenue $128.4M, net income -$37.3MQuarter to 31 Dec 2022: revenue $128.4M, net income -$37.3MQuarter to 31 Mar 2023: revenue $122.2M, net income -$53.1MQuarter to 31 Mar 2023: revenue $122.2M, net income -$53.1MQuarter to 30 Jun 2023: revenue $126.1M, net income -$57.4MQuarter to 30 Jun 2023: revenue $126.1M, net income -$57.4MQuarter to 30 Sep 2023: revenue $127.3M, net income -$49.5MQuarter to 30 Sep 2023: revenue $127.3M, net income -$49.5MQuarter to 31 Dec 2023: revenue $133.8M, net income -$47.1MQuarter to 31 Dec 2023: revenue $133.8M, net income -$47.1MQuarter to 31 Mar 2024: revenue $138.5M, net income -$38.8MQuarter to 31 Mar 2024: revenue $138.5M, net income -$38.8MQuarter to 30 Jun 2024: revenue $150.4M, net income -$33.4MQuarter to 30 Jun 2024: revenue $150.4M, net income -$33.4MQuarter to 30 Sep 2024: revenue $155.1M, net income -$30.6MQuarter to 30 Sep 2024: revenue $155.1M, net income -$30.6MQuarter to 31 Dec 2024: revenue $161.3M, net income -$65.9MQuarter to 31 Dec 2024: revenue $161.3M, net income -$65.9MQuarter to 31 Mar 2025: revenue $155.0M, net income -$34.3MQuarter to 31 Mar 2025: revenue $155.0M, net income -$34.3MQuarter to 30 Jun 2025: revenue $158.8M, net income -$40.1MQuarter to 30 Jun 2025: revenue $158.8M, net income -$40.1MQuarter to 30 Sep 2025: revenue $167.2M, net income -$37.3MQuarter to 30 Sep 2025: revenue $167.2M, net income -$37.3MQuarter to 31 Dec 2025: revenue $174.3M, net income -$24.5MQuarter to 31 Dec 2025: revenue $174.3M, net income -$24.5MQuarter to 31 Mar 2026: revenue $174.1M, net income -$71.1MQuarter to 31 Mar 2026: revenue $174.1M, net income -$71.1MQuarter to 30 Jun 2026: revenue $183.6M, net income -$15.7MQuarter to 30 Jun 2026: revenue $183.6M, net income -$15.7MQuarter to 30 Sep 2026: revenue $193.4M, net income -$10.4MQuarter to 30 Sep 2026: revenue $193.4M, net income -$10.4M
31 Dec 2021RevenueNet incomeNet losstallest bar $193.4M30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026$193.4M-$10.4M
30 Jun 2026$183.6M-$15.7M
31 Mar 2026$174.1M-$71.1M
31 Dec 2025$174.3M-$24.5M
30 Sep 2025$167.2M-$37.3M
30 Jun 2025$158.8M-$40.1M
31 Mar 2025$155.0M-$34.3M
31 Dec 2024$161.3M-$65.9M
30 Sep 2024$155.1M-$30.6M
30 Jun 2024$150.4M-$33.4M
31 Mar 2024$138.5M-$38.8M
31 Dec 2023$133.8M-$47.1M
30 Sep 2023$127.3M-$49.5M
30 Jun 2023$126.1M-$57.4M
31 Mar 2023$122.2M-$53.1M
31 Dec 2022$128.4M-$37.3M
30 Sep 2022$131.0M-$26.6M
30 Jun 2022$140.9M-$24.0M
31 Mar 2022$137.5M-$4.6M
31 Dec 2021$133.2M-$26.5M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. $725.4M $642.3M
Revenue growthRevenue of the last 12 months compared with the 12 months before. +13% +13%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. -$121.7M -$177.7M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). -$1.06 -$1.61
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. 77.0% 75.4% 60.5%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. -17.2% -27.5% -8.3%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. -16.8% -27.7% -10.1%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. -35.2% -26.3%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. -$24.6M -$65.2M
CashCash, cash equivalents and short-term investments on the latest balance sheet. $96.7M $342.1M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. – $755.3M
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). – $413.1M
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. – 0.31
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $3.00
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. loss 28.0
P/SPrice to sales: market cap divided by revenue of the last 12 months. 1.7 2.3
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. – 2.5
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 3.6 2.8

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
NovoCureNVCR (this company) $1.3Bloss1.7+13%-16.8%
Tandem Diabetes CareTNDM $1.2Bloss1.1+6.8%-4.6%
PROCEPT BioRoboticsPRCT $1.4Bloss4.0+17%-32.6%
Si-BoneSIBN $1.1Bloss4.9+14%-6.2%
Kestra Medical TechnologiesKMTS $1.5Bloss14.0+61%-140%
iRadimedIRMD $1.0B43.211.6+11%26.8%

Insider Buy/Sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

-$143K

bought $0, sold $143K

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

+13%

239 13F filers vs 212

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

88%

103.3M shares held by 13F filers (30 Sep 2026) of 116.9M outstanding (23 Oct 2026)

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

11%

12.9M shares sold short (30 Oct 2026) of 116.9M outstanding (23 Oct 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

6.0

12.9M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

+0.7%

12.8M shares sold short in the report before, 12.9M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

60%

60% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 48%

Open jobs Job postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.

47

Tracked since 21 Nov 2026

Open jobs change How the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.

–

Tracking started 21 Nov 2026; the change shows after 30 days.

Employees Total staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.

–

No headcount in its annual reports in our data.

Visa hiring (foreign workers) Applications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.

–

No data for this company

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

+16%

$193.4M vs $167.2M (quarter ended 30 Sep 2026)

Capital spending Money spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.

+22%

$6.9M vs $5.7M (quarter ended 30 Sep 2026)

Federal contracts Money the US government committed to the company in contracts and grants over the last 12 months.

$11.0M

the 12 months before: $8.6M

Lobbying What the company reported spending on federal lobbying over the last four quarters.

$610K

4 quarters, $

Layoff notices Workers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).

–

No data for this company

News (7d) Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

2

2 articles in the last 7 days; its usual week has 2 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

1.0×

2 articles in the last 7 days; its usual week has 2.

Price $10.71 on 20 Nov 2026, -6.5% over 12 months (12-month range $10.03 to $19.99)

  • Sharp change
  • 8-K and other filings
  • Lobbying filing
Insider net buying (open market). Insiders sold a net $3.3M in the last 12 months (the 12 months before: -$338K).
H-1B/E-3 applications certified. H-1B/E-3 applications certified: 2 published in the last 12 months, 0% on the 12 months before.
Revenue per quarter. Revenue $193.4M in the latest quarter, +16% on a year earlier.
Capital spending per quarter. Capital spending $6.9M in the latest quarter, +22% on a year earlier.
Institutional holders (13F filers). 239 13F filers reported holding it in the latest 13F quarter, +2.6% on a year earlier.
Federal obligations. Federal obligations: $13.5M published in the last 12 months, +70% on the 12 months before.
Lobbying spend. Lobbying spend: $610K published in the last 12 months, +39% on the 12 months before.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
9 Sep 20268-K and other filingsDirector or officer change
9 Sep 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
5 Jun 20268-K and other filingsDirector or officer change
14 Apr 2026Sharp changeShort interest spike: short interest spike, 9.1M vs usual 5.7M (2026-03-31); 1.7x the same period a year earlier
9 Apr 20268-K and other filingsDirector or officer change
9 Apr 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
31 Mar 2026Sharp changeShort interest spike: short interest spike, 8.5M vs usual 5.6M (2026-03-13); 1.6x the same period a year earlier
17 Mar 2026Sharp changeShort interest spike: short interest spike, 9.1M vs usual 5.5M (2026-02-27); 1.7x the same period a year earlier
3 Mar 2026Sharp changeShort interest spike: short interest spike, 8.9M vs usual 5.4M (2026-02-13); 1.7x the same period a year earlier
17 Feb 2026Sharp changeShort interest spike: short interest spike, 8.0M vs usual 5.4M (2026-01-30); 1.6x the same period a year earlier
3 Feb 2026Sharp changeShort interest spike: short interest spike, 7.4M vs usual 5.4M (2026-01-15); 1.5x the same period a year earlier
21 Jan 2026Sharp changeLobbying on a new issue: lobbying on a new issue: PHA, TAR, TRD (2025-12-31)
21 Jan 2026Lobbying filingnew lobbying registration (MAYER BROWN LLP)
13 Jan 2026Sharp changeShort interest spike: short interest spike, 8.3M vs usual 5.4M (2025-12-31); 1.5x the same period a year earlier
1 Dec 20258-K and other filingsDirector or officer change
1 Dec 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
20 Nov 2025Lobbying filingnew lobbying registration (WILLIAMS AND JENSEN, PLLC)
6 Jun 20258-K and other filingsDirector or officer change
6 Jun 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
30 Oct 20248-K and other filingsDirector or officer change
3 Sep 20248-K and other filingsDirector or officer change
30 Jul 2024Sharp changeQuarterly capital spending jump: quarterly capital spending jump, 11.4M vs usual 6.6M (2024-06-30); 1.7x the same period a year earlier
23 Jul 2024Sharp changeLobbying spend jump: lobbying spend jump, 220K vs usual 120K (2024-06-30); 1.2x the same period a year earlier
10 Jun 20248-K and other filingsDirector or officer change
10 Jun 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
7 May 2024Sharp changeQuarterly capital spending jump: quarterly capital spending jump, 11.8M vs usual 6.3M (2024-03-31); 1.9x the same period a year earlier
23 Apr 2024Sharp changeLobbying spend jump: lobbying spend jump, 200K vs usual 120K (2024-03-31); 1.7x the same period a year earlier
4 Jan 20248-K and other filingsDirector or officer change
4 Jan 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
8 Jun 20238-K and other filingsDirector or officer change
29 Mar 20238-K and other filingsDirector or officer change
29 Mar 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
21 Jan 2023Sharp changeLobbying on a new issue: lobbying on a new issue: TRA (2022-12-31)
10 Jun 20228-K and other filingsDirector or officer change
31 May 2022Sharp changeShort interest spike: short interest spike, 8.2M vs usual 5.4M (2022-05-13); 1.6x the same period a year earlier
17 May 2022Sharp changeShort interest spike: short interest spike, 7.8M vs usual 5.4M (2022-04-29); 1.6x the same period a year earlier
3 May 2022Sharp changeShort interest spike: short interest spike, 7.4M vs usual 5.4M (2022-04-14); 1.5x the same period a year earlier
13 Apr 20228-K and other filingsDirector or officer change
13 Apr 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
12 Apr 2022Sharp changeShort interest spike: short interest spike, 7.5M vs usual 5.4M (2022-03-31); 1.6x the same period a year earlier
1 Mar 2022Sharp changeShort interest spike: short interest spike, 7.2M vs usual 5.3M (2022-02-15); 1.5x the same period a year earlier
11 Feb 2022Lobbying filingnew lobbying registration (in-house)
20 Jan 2022Lobbying filinglobbying engagement terminated (FOLEY & LARDNER LLP)
Insider net buying (open market)
Month from 1 Nov 2021: $510K published
Month from 1 Jan 2022: -$300K published
Month from 1 Mar 2022: -$2.9M published
Month from 1 May 2022: -$266K published
Month from 1 Jun 2022: -$28K published
Month from 1 Aug 2022: -$557K published
Month from 1 Sep 2022: -$3.2M published
Month from 1 Oct 2022: -$1.6M published
Month from 1 Jan 2023: -$28.5M published
Month from 1 Mar 2023: -$6.5M published
Month from 1 Aug 2023: -$35K published
Month from 1 Sep 2023: -$32K published
Month from 1 Nov 2023: -$5K published
Month from 1 Mar 2024: -$164K published
Month from 1 Jun 2024: -$69K published
Month from 1 Aug 2024: -$14K published
Month from 1 Nov 2024: -$26K published
Month from 1 Jan 2025: -$58K published
Month from 1 Mar 2025: -$831K published
Month from 1 May 2025: -$11K published
Month from 1 Jun 2025: -$667K published
Month from 1 Jul 2025: $232K published
Month from 1 Sep 2025: $997K published
Month from 1 Mar 2026: -$2.3M published
Month from 1 Jun 2026: -$893K published
Month from 1 Nov 2026: -$143K published
H-1B/E-3 applications certified
Quarter from 1 Oct 2023: 1 published
Quarter from 1 Jul 2025: 2 published
Quarter from 1 Jul 2026: 2 published
Revenue per quarter
Quarter ended 31 Dec 2021: $133.2M, -7.5% on a year earlier; public on 25 Feb 2022
Quarter ended 31 Mar 2022: $137.5M, +2.1% on a year earlier; public on 29 Apr 2022
Quarter ended 30 Jun 2022: $140.9M, +5.5% on a year earlier; public on 29 Jul 2022
Quarter ended 30 Sep 2022: $131.0M, -2.0% on a year earlier; public on 28 Oct 2022
Quarter ended 31 Dec 2022: $128.4M, -3.6% on a year earlier; public on 24 Feb 2023
Quarter ended 31 Mar 2023: $122.2M, -11% on a year earlier; public on 5 May 2023
Quarter ended 30 Jun 2023: $126.1M, -11% on a year earlier; public on 28 Jul 2023
Quarter ended 30 Sep 2023: $127.3M, -2.8% on a year earlier; public on 27 Oct 2023
Quarter ended 31 Dec 2023: $133.8M, +4.2% on a year earlier; public on 23 Feb 2024
Quarter ended 31 Mar 2024: $138.5M, +13% on a year earlier; public on 3 May 2024
Quarter ended 30 Jun 2024: $150.4M, +19% on a year earlier; public on 26 Jul 2024
Quarter ended 30 Sep 2024: $155.1M, +22% on a year earlier; public on 31 Oct 2024
Quarter ended 31 Dec 2024: $161.3M, +21% on a year earlier; public on 28 Feb 2025
Quarter ended 31 Mar 2025: $155.0M, +12% on a year earlier; public on 25 Apr 2025
Quarter ended 30 Jun 2025: $158.8M, +5.6% on a year earlier; public on 25 Jul 2025
Quarter ended 30 Sep 2025: $167.2M, +7.8% on a year earlier; public on 31 Oct 2025
Quarter ended 31 Dec 2025: $174.3M, +8.1% on a year earlier; public on 27 Feb 2026
Quarter ended 31 Mar 2026: $174.1M, +12% on a year earlier; public on 1 May 2026
Quarter ended 30 Jun 2026: $183.6M, +16% on a year earlier; public on 24 Jul 2026
Quarter ended 30 Sep 2026: $193.4M, +16% on a year earlier; public on 30 Oct 2026
Capital spending per quarter
Quarter ended 31 Dec 2021: $14.3M; public on 25 Feb 2022
Quarter ended 31 Mar 2022: $5.1M, +28% on a year earlier; public on 29 Apr 2022
Quarter ended 30 Jun 2022: $4.1M, +58% on a year earlier; public on 29 Jul 2022
Quarter ended 30 Sep 2022: $5.7M, +73% on a year earlier; public on 28 Oct 2022
Quarter ended 31 Dec 2022: $6.4M, -55% on a year earlier; public on 24 Feb 2023
Quarter ended 31 Mar 2023: $6.1M, +20% on a year earlier; public on 5 May 2023
Quarter ended 30 Jun 2023: $6.9M, +68% on a year earlier; public on 28 Jul 2023
Quarter ended 30 Sep 2023: $7.3M, +27% on a year earlier; public on 27 Oct 2023
Quarter ended 31 Dec 2023: $6.8M, +6.1% on a year earlier; public on 23 Feb 2024
Quarter ended 31 Mar 2024: $11.8M, +94% on a year earlier; public on 3 May 2024
Quarter ended 30 Jun 2024: $11.4M, +65% on a year earlier; public on 26 Jul 2024
Quarter ended 30 Sep 2024: $10.7M, +47% on a year earlier; public on 31 Oct 2024
Quarter ended 31 Dec 2024: $8.9M, +31% on a year earlier; public on 28 Feb 2025
Quarter ended 31 Mar 2025: $10.6M, -10% on a year earlier; public on 25 Apr 2025
Quarter ended 30 Jun 2025: $5.5M, -52% on a year earlier; public on 25 Jul 2025
Quarter ended 30 Sep 2025: $5.7M, -47% on a year earlier; public on 31 Oct 2025
Quarter ended 31 Dec 2025: $4.9M, -45% on a year earlier; public on 27 Feb 2026
Quarter ended 31 Mar 2026: $5.2M, -51% on a year earlier; public on 1 May 2026
Quarter ended 30 Jun 2026: $6.9M, +26% on a year earlier; public on 24 Jul 2026
Quarter ended 30 Sep 2026: $6.9M, +22% on a year earlier; public on 30 Oct 2026
Institutional holders (13F filers)
31 Dec 2021 report: 286; public on 14 Feb 2022
31 Mar 2022 report: 288; public on 16 May 2022
30 Jun 2022 report: 299; public on 15 Aug 2022
30 Sep 2022 report: 276; public on 14 Nov 2022
31 Dec 2022 report: 281; public on 14 Feb 2023
31 Mar 2023 report: 276; public on 15 May 2023
30 Jun 2023 report: 249; public on 14 Aug 2023
30 Sep 2023 report: 212; public on 14 Nov 2023
31 Dec 2023 report: 206; public on 14 Feb 2024
31 Mar 2024 report: 231; public on 15 May 2024
30 Jun 2024 report: 223; public on 14 Aug 2024
30 Sep 2024 report: 215; public on 14 Nov 2024
31 Dec 2024 report: 234; public on 14 Feb 2025
31 Mar 2025 report: 223; public on 15 May 2025
30 Jun 2025 report: 232; public on 14 Aug 2025
30 Sep 2025 report: 233; public on 14 Nov 2025
31 Dec 2025 report: 229; public on 17 Feb 2026
31 Mar 2026 report: 217; public on 15 May 2026
30 Jun 2026 report: 212; public on 14 Aug 2026
30 Sep 2026 report: 239; public on 16 Nov 2026
Federal obligations
Month from 1 Nov 2021: $21K published
Month from 1 Dec 2021: $357K published
Month from 1 Jan 2022: $609K published
Month from 1 Feb 2022: $462K published
Month from 1 Mar 2022: $668K published
Month from 1 Apr 2022: $470K published
Month from 1 May 2022: $861K published
Month from 1 Jun 2022: $642K published
Month from 1 Jul 2022: $810K published
Month from 1 Aug 2022: $798K published
Month from 1 Sep 2022: $264K published
Month from 1 Oct 2022: $512K published
Month from 1 Nov 2022: $454K published
Month from 1 Dec 2022: $346K published
Month from 1 Jan 2023: $373K published
Month from 1 Feb 2023: -$84K published
Month from 1 Mar 2023: $841K published
Month from 1 Apr 2023: $219K published
Month from 1 May 2023: $604K published
Month from 1 Jun 2023: $671K published
Month from 1 Jul 2023: $562K published
Month from 1 Aug 2023: $933K published
Month from 1 Sep 2023: $907K published
Month from 1 Oct 2023: $648K published
Month from 1 Nov 2023: $632K published
Month from 1 Dec 2023: $462K published
Month from 1 Jan 2024: $1.1M published
Month from 1 Feb 2024: $880K published
Month from 1 Mar 2024: $571K published
Month from 1 Apr 2024: $941K published
Month from 1 May 2024: $479K published
Month from 1 Jun 2024: $709K published
Month from 1 Jul 2024: $796K published
Month from 1 Aug 2024: $796K published
Month from 1 Sep 2024: $803K published
Month from 1 Oct 2024: $684K published
Month from 1 Nov 2024: $808K published
Month from 1 Dec 2024: $924K published
Month from 1 Jan 2025: $417K published
Month from 1 Feb 2025: $658K published
Month from 1 Mar 2025: $626K published
Month from 1 Apr 2025: $676K published
Month from 1 May 2025: $763K published
Month from 1 Jun 2025: $576K published
Month from 1 Jul 2025: $746K published
Month from 1 Aug 2025: $995K published
Month from 1 Sep 2025: $460K published
Month from 1 Oct 2025: $431K published
Month from 1 Nov 2025: $696K published
Month from 1 Dec 2025: $730K published
Month from 1 Jan 2026: $497K published
Month from 1 Feb 2026: $879K published
Month from 1 Mar 2026: $1.3M published
Month from 1 Apr 2026: $1.3M published
Month from 1 May 2026: $1.1M published
Month from 1 Jun 2026: $1.4M published
Month from 1 Jul 2026: $1.0M published
Month from 1 Aug 2026: $1.8M published
Month from 1 Sep 2026: $1.3M published
Month from 1 Oct 2026: $846K published
Month from 1 Nov 2026: $1.3M published
Lobbying spend
Quarter from 1 Jan 2022: $80K published
Quarter from 1 Apr 2022: $110K published
Quarter from 1 Jul 2022: $120K published
Quarter from 1 Oct 2022: $120K published
Quarter from 1 Jan 2023: $120K published
Quarter from 1 Apr 2023: $120K published
Quarter from 1 Jul 2023: $180K published
Quarter from 1 Oct 2023: $140K published
Quarter from 1 Jan 2024: $120K published
Quarter from 1 Apr 2024: $200K published
Quarter from 1 Jul 2024: $220K published
Quarter from 1 Oct 2024: $120K published
Quarter from 1 Jan 2025: $110K published
Quarter from 1 Apr 2025: $110K published
Quarter from 1 Jul 2025: $110K published
Quarter from 1 Oct 2025: $110K published
Quarter from 1 Jan 2026: $110K published
Quarter from 1 Apr 2026: $180K published
Quarter from 1 Jul 2026: $160K published
Quarter from 1 Oct 2026: $160K published

What is unusual now

  • Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is lobbying spend reported (quarter) at $160K (30 Sep 2026), 1.5× its normal reading; higher than 87% of its own history.
  • Insider net buying (open market): Insiders sold a net $3.3M in the last 12 months (the 12 months before: -$338K).
  • H-1B/E-3 applications certified: H-1B/E-3 applications certified: 2 published in the last 12 months, 0% on the 12 months before.
  • Revenue per quarter: Revenue $193.4M in the latest quarter, +16% on a year earlier.

Latest records

The names and amounts behind the totals, newest first

Last 90 days: 3 sales, $143K; no purchases. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
12 Nov 2026Mukund ParavasthuChief Operating OfficerSell3,079$12.86$40KForm 4
12 Nov 2026Christoph BrackmannChief Financial OfficerSell7,343$12.86$94KForm 4
4 Nov 2026Michal Nath PuriChief Human Resources OfficerSell660$13.24$9KForm 4
5 Jun 2026Frank X LeonardChief Executive OfficerSell34,273$17.93$615KForm 4
3 Jun 2026Allyson J OceanDirectorSell2,945$15.77$46KForm 4
3 Jun 2026W Anthony VernonDirectorSell2,945$15.77$46KForm 4
3 Jun 2026David HungDirectorSell2,945$15.77$46KForm 4
3 Jun 2026Gabriel LeungDirectorSell2,945$15.77$46KForm 4

239 institutions reported shares at the end of Q3 2026, 88% of the shares outstanding; 43 opened a position, 20 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
FMR LLC (Fidelity)17.4M14.9%$277.1M+2,7770%
BlackRock, Inc.11.9M10.1%$189.2M-1.5M-12%
Soleus Capital Management, L.P.9.4M8.06%$150.3M-488K-4.9%
Vanguard Portfolio Management LLC6.5M5.55%$103.6M+221K+3.5%
Vanguard Capital Management LLC4.9M4.21%$78.5M+20K+0.4%
Morgan Stanley4.7M4.02%$74.9M+175K+3.9%
Quantinno Capital Management LP4.2M3.61%$67.4M+2.0M+90%
State Street Corp2.9M2.50%$46.7M+61K+2.1%
Geode Capital Management, LLC2.8M2.40%$44.8M+8,913+0.3%
Wells Fargo & Company2.3M1.93%$36.0M-269K-11%

Company events

All 49 company events

In 12 months: 4 director or officer changes. Results releases and routine reports are left out.

FiledWhat happenedSource
9 Sep 2026Director or officer change8-K
5 Jun 2026Director or officer changeSame filing: shareholder vote results8-K
9 Apr 2026Director or officer change8-K
1 Dec 2025Director or officer change8-K
6 Jun 2025Director or officer changeSame filing: shareholder vote results8-K
30 Oct 2024Director or officer change8-K
3 Sep 2024Director or officer change8-K
10 Jun 2024Director or officer changeSame filing: shareholder vote results8-K

47 open postings; careers site tracked since 21 Nov 2026. Most in Customer success & support 30%, Sales & business development 15%, Finance & accounting 11%, Operations & administration 9%.

PostedJobLocation
21 Nov 2026or earlierManager, Clinical AppealsFinance & accountingPortsmouth, NH, US, 03801
21 Nov 2026or earlierOffice Coordinator, SpainExecutive & administrative supportES
21 Nov 2026or earlierHead of Procure-to-PayFinance & accountingPL
21 Nov 2026or earlierProduct and Business Analyst - Scrum MasterProgram & project managementPL
21 Nov 2026or earlierTechnical Support Engineer - Medical DevicesCustomer success & supportPL
21 Nov 2026or earlierSAP ABAP DeveloperSoftware engineeringPL
21 Nov 2026or earlierSenior Manager, Process Excellence & TransformationFinance & accountingPL
21 Nov 2026or earlierSenior Business Intelligence DeveloperData & analyticsPL

Reported lobbying spend: $160K in Q3 2026, $160K in Q2 2026. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.

DateChangeLobbying firmIssueSource
5 Dec 2025NewMayer Brown LLPfor NovocureGeneral issues pertaining to Section 301 investigations.MED, TARFiling
8 Oct 2025NewWilliams And Jensen, PLLCfor Novocure Inc.Lobbying for the breakthrough pathway bill (H.R. 5343, S. 1717), CMS reimbursement of medical devices generally, and FDA issues related to medical devices.Pharmacy, VETFiling
1 Jan 2022NewNovocure Inc.its own lobbyistsGeneral Medicare / Medicaid IssuesMedicare/MedicaidFiling
31 Dec 2021EndedFoley & Lardner LLPfor Novocure Inc.Not statedFiling
1 Sep 2021NewTarplin, Downs & Young, LLCfor Novocure Inc.Medicare coverage and reimbursementHealth issues, Medicare/Medicaid, BudgetFiling
10 Oct 2017NewFoley & Lardner LLPfor Novocure Inc.Advocate for client before members of th eU.S. House of Representatives, U.S. Senate, and staffs to each, and the Centers for Medicare and Medicaid Services, with respect to coverage and pricing issues; review relevant statutes and regulations regarding same; advise clients with respect to same.Health issues, Copyright/patents, VET, Budget, Insurance, MED, Science/technology, Manufacturing, Medicare/MedicaidFiling
8 Oct 2017EndedRubin And Rudman LLPfor Novocure Inc.Advocate for client before members of the U.S. House of Representatives, U.S. Senate, and staffs to each, and before the Department of Health and Human Services, sub-agencies, and staffs to each, with respect to coverage and pricing issues; review relevant statutes and regulations regarding same.Health issuesFiling
30 Jun 2015EndedSidley Austin LLPfor Novocure Inc.Not statedFiling

The 5 newest of 120 articles that name the company.

Timeline

Several things at once

Two or more unrelated kinds of records unusual within 30 days

21 Jan 2026confirmed

Confirmed across sources Lobbying and Short interest and volume

NovoCure (NVCR): lobbying on a new issue, while it had 9.1M shares sold short in the 27 Feb 2026 report, 1.7× the same report last year. Two unrelated kinds of activity within 91 days.

  • Short interest and volume: Short interest spike, became public on 13 Jan 2026
  • Lobbying: Lobbying on a new issue, became public on 21 Jan 2026
  • Short interest and volume: Short interest spike, became public on 28 Jan 2026
  • Short interest and volume: Short interest spike, became public on 11 Feb 2026
  • Short interest and volume: Short interest spike, became public on 26 Feb 2026
  • Short interest and volume: Short interest spike, became public on 11 Mar 2026
  • Short interest and volume: Short interest spike, became public on 25 Mar 2026
  • Short interest and volume: Short interest spike, became public on 11 Apr 2026
2025-02-28: 5.2M2025-03-14: 5.4M2025-03-31: 5.4M2025-04-15: 5.1M2025-04-30: 5.4M2025-05-15: 5.4M2025-05-30: 4.6M2025-06-13: 4.9M2025-06-30: 5.2M2025-07-15: 4.9M2025-07-31: 5.2M2025-08-15: 5.5M2025-08-29: 6.0M2025-09-15: 5.9M2025-09-30: 5.7M2025-10-15: 5.2M2025-10-31: 5.7M2025-11-14: 6.0M2025-11-28: 6.8M2025-12-15: 6.9M2025-12-31: 8.3M2026-01-15: 7.4M2026-01-30: 8.0M2026-02-13: 8.9M2026-02-27: 9.1M
The 27 Feb 2026 report against the 24 reports before it. this reportearliernormal: 5.5M
See the evidence (8 changes)

Short interest and volume: Short interest spike became public on 13 Jan 2026

NovoCure had 8.3M shares sold short in the 31 Dec 2025 report, 1.5× the same report last year.

This period
8.3M (the 31 Dec 2025 report)
Normal report (median of 24 earlier)
5.4M
Typical spread (median absolute deviation)
288K
How far from its usual level
+5.4
Same report last year
5.4M
History used
2,924 days
2024-12-31: 5.4M2025-01-15: 4.9M2025-01-31: 5.0M2025-02-14: 5.2M2025-02-28: 5.2M2025-03-14: 5.4M2025-03-31: 5.4M2025-04-15: 5.1M2025-04-30: 5.4M2025-05-15: 5.4M2025-05-30: 4.6M2025-06-13: 4.9M2025-06-30: 5.2M2025-07-15: 4.9M2025-07-31: 5.2M2025-08-15: 5.5M2025-08-29: 6.0M2025-09-15: 5.9M2025-09-30: 5.7M2025-10-15: 5.2M2025-10-31: 5.7M2025-11-14: 6.0M2025-11-28: 6.8M2025-12-15: 6.9M2025-12-31: 8.3M
the 31 Dec 2025 report24 earlier reportsnormal: 5.4M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Lobbying: Lobbying on a new issue became public on 21 Jan 2026

NovoCure lobbying on a new issue.

New
['PHA', 'TAR', 'TRD']
Rule
only points whose every posting (and value revision) is at or before as_of
Field
issue_codes
Metric
lobbying.filings_count
Point id
4689088

Short interest and volume: Short interest spike became public on 28 Jan 2026

NovoCure had 7.4M shares sold short in the 15 Jan 2026 report, 1.5× the same report last year.

This period
7.4M (the 15 Jan 2026 report)
Normal report (median of 24 earlier)
5.4M
Typical spread (median absolute deviation)
331K
How far from its usual level
+3.8
Same report last year
4.9M
History used
2,939 days
2025-01-15: 4.9M2025-01-31: 5.0M2025-02-14: 5.2M2025-02-28: 5.2M2025-03-14: 5.4M2025-03-31: 5.4M2025-04-15: 5.1M2025-04-30: 5.4M2025-05-15: 5.4M2025-05-30: 4.6M2025-06-13: 4.9M2025-06-30: 5.2M2025-07-15: 4.9M2025-07-31: 5.2M2025-08-15: 5.5M2025-08-29: 6.0M2025-09-15: 5.9M2025-09-30: 5.7M2025-10-15: 5.2M2025-10-31: 5.7M2025-11-14: 6.0M2025-11-28: 6.8M2025-12-15: 6.9M2025-12-31: 8.3M2026-01-15: 7.4M
the 15 Jan 2026 report24 earlier reportsnormal: 5.4M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 11 Feb 2026

NovoCure had 8.0M shares sold short in the 30 Jan 2026 report, 1.6× the same report last year.

This period
8.0M (the 30 Jan 2026 report)
Normal report (median of 24 earlier)
5.4M
Typical spread (median absolute deviation)
319K
How far from its usual level
+4.7
Same report last year
5.0M
History used
2,954 days
2025-01-31: 5.0M2025-02-14: 5.2M2025-02-28: 5.2M2025-03-14: 5.4M2025-03-31: 5.4M2025-04-15: 5.1M2025-04-30: 5.4M2025-05-15: 5.4M2025-05-30: 4.6M2025-06-13: 4.9M2025-06-30: 5.2M2025-07-15: 4.9M2025-07-31: 5.2M2025-08-15: 5.5M2025-08-29: 6.0M2025-09-15: 5.9M2025-09-30: 5.7M2025-10-15: 5.2M2025-10-31: 5.7M2025-11-14: 6.0M2025-11-28: 6.8M2025-12-15: 6.9M2025-12-31: 8.3M2026-01-15: 7.4M2026-01-30: 8.0M
the 30 Jan 2026 report24 earlier reportsnormal: 5.4M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 26 Feb 2026

NovoCure had 8.9M shares sold short in the 13 Feb 2026 report, 1.7× the same report last year.

This period
8.9M (the 13 Feb 2026 report)
Normal report (median of 24 earlier)
5.4M
Typical spread (median absolute deviation)
305K
How far from its usual level
+6.4
Same report last year
5.2M
History used
2,968 days
2025-02-14: 5.2M2025-02-28: 5.2M2025-03-14: 5.4M2025-03-31: 5.4M2025-04-15: 5.1M2025-04-30: 5.4M2025-05-15: 5.4M2025-05-30: 4.6M2025-06-13: 4.9M2025-06-30: 5.2M2025-07-15: 4.9M2025-07-31: 5.2M2025-08-15: 5.5M2025-08-29: 6.0M2025-09-15: 5.9M2025-09-30: 5.7M2025-10-15: 5.2M2025-10-31: 5.7M2025-11-14: 6.0M2025-11-28: 6.8M2025-12-15: 6.9M2025-12-31: 8.3M2026-01-15: 7.4M2026-01-30: 8.0M2026-02-13: 8.9M
the 13 Feb 2026 report24 earlier reportsnormal: 5.4M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 11 Mar 2026

NovoCure had 9.1M shares sold short in the 27 Feb 2026 report, 1.7× the same report last year.

This period
9.1M (the 27 Feb 2026 report)
Normal report (median of 24 earlier)
5.5M
Typical spread (median absolute deviation)
375K
How far from its usual level
+6.6
Same report last year
5.2M
History used
2,982 days
2025-02-28: 5.2M2025-03-14: 5.4M2025-03-31: 5.4M2025-04-15: 5.1M2025-04-30: 5.4M2025-05-15: 5.4M2025-05-30: 4.6M2025-06-13: 4.9M2025-06-30: 5.2M2025-07-15: 4.9M2025-07-31: 5.2M2025-08-15: 5.5M2025-08-29: 6.0M2025-09-15: 5.9M2025-09-30: 5.7M2025-10-15: 5.2M2025-10-31: 5.7M2025-11-14: 6.0M2025-11-28: 6.8M2025-12-15: 6.9M2025-12-31: 8.3M2026-01-15: 7.4M2026-01-30: 8.0M2026-02-13: 8.9M2026-02-27: 9.1M
the 27 Feb 2026 report24 earlier reportsnormal: 5.5M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 25 Mar 2026

NovoCure had 8.5M shares sold short in the 13 Mar 2026 report, 1.6× the same report last year.

This period
8.5M (the 13 Mar 2026 report)
Normal report (median of 24 earlier)
5.6M
Typical spread (median absolute deviation)
384K
How far from its usual level
+5.1
Same report last year
5.4M
History used
2,996 days
2025-03-14: 5.4M2025-03-31: 5.4M2025-04-15: 5.1M2025-04-30: 5.4M2025-05-15: 5.4M2025-05-30: 4.6M2025-06-13: 4.9M2025-06-30: 5.2M2025-07-15: 4.9M2025-07-31: 5.2M2025-08-15: 5.5M2025-08-29: 6.0M2025-09-15: 5.9M2025-09-30: 5.7M2025-10-15: 5.2M2025-10-31: 5.7M2025-11-14: 6.0M2025-11-28: 6.8M2025-12-15: 6.9M2025-12-31: 8.3M2026-01-15: 7.4M2026-01-30: 8.0M2026-02-13: 8.9M2026-02-27: 9.1M2026-03-13: 8.5M
the 13 Mar 2026 report24 earlier reportsnormal: 5.6M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 11 Apr 2026

NovoCure had 9.1M shares sold short in the 31 Mar 2026 report, 1.7× the same report last year.

This period
9.1M (the 31 Mar 2026 report)
Normal report (median of 24 earlier)
5.7M
Typical spread (median absolute deviation)
548K
How far from its usual level
+4.1
Same report last year
5.4M
History used
3,014 days
2025-03-31: 5.4M2025-04-15: 5.1M2025-04-30: 5.4M2025-05-15: 5.4M2025-05-30: 4.6M2025-06-13: 4.9M2025-06-30: 5.2M2025-07-15: 4.9M2025-07-31: 5.2M2025-08-15: 5.5M2025-08-29: 6.0M2025-09-15: 5.9M2025-09-30: 5.7M2025-10-15: 5.2M2025-10-31: 5.7M2025-11-14: 6.0M2025-11-28: 6.8M2025-12-15: 6.9M2025-12-31: 8.3M2026-01-15: 7.4M2026-01-30: 8.0M2026-02-13: 8.9M2026-02-27: 9.1M2026-03-13: 8.5M2026-03-31: 9.1M
the 31 Mar 2026 report24 earlier reportsnormal: 5.7M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

30 Jul 2024confirmed

Confirmed across sources Filings + Financials and Lobbying

NovoCure (NVCR): reported $220K of lobbying spend for the quarter ended 30 Jun 2024, 1.2× the same quarter last year, while it spent $11.4M on capital projects in the quarter ended 30 Jun 2024, 1.7× the same quarter last year. Two unrelated kinds of activity within 7 days.

  • Lobbying: Lobbying spend jump, became public on 22 Jul 2024
  • Financials: Quarterly capital spending jump, became public on 30 Jul 2024
2022-06-30: $120K2022-09-30: $120K2022-12-31: $120K2023-03-31: $120K2023-06-30: $180K2023-09-30: $140K2023-12-31: $120K2024-03-31: $200K2024-06-30: $220K
The quarter ended 30 Jun 2024 against the 8 quarters before it. this quarterearliernormal: $120K
See the evidence (2 changes)

Lobbying: Lobbying spend jump became public on 22 Jul 2024

NovoCure reported $220K of lobbying spend for the quarter ended 30 Jun 2024, 1.2× the same quarter last year.

This period
$220K (the quarter ended 30 Jun 2024)
Normal quarter (median of 8 earlier)
$120K
Typical spread (median absolute deviation)
$0
How far from its usual level
+5.0
Same quarter last year
$180K
History used
3,834 days
2022-06-30: $120K2022-09-30: $120K2022-12-31: $120K2023-03-31: $120K2023-06-30: $180K2023-09-30: $140K2023-12-31: $120K2024-03-31: $200K2024-06-30: $220K
the quarter ended 30 Jun 20248 earlier quartersnormal: $120K

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least $100K.

Check it at the source: Senate/House lobbying disclosures (LDA).

Financials: Quarterly capital spending jump became public on 30 Jul 2024

NovoCure spent $11.4M on capital projects in the quarter ended 30 Jun 2024, 1.7× the same quarter last year.

This period
$11.4M (the quarter ended 30 Jun 2024)
Normal quarter (median of 8 earlier)
$6.6M
Typical spread (median absolute deviation)
$582K
How far from its usual level
+4.8
Same quarter last year
$6.9M
History used
3,469 days
2022-06-30: $4.1M2022-09-30: $5.7M2022-12-31: $6.4M2023-03-31: $6.1M2023-06-30: $6.9M2023-09-30: $7.3M2023-12-31: $6.8M2024-03-31: $11.8M2024-06-30: $11.4M
the quarter ended 30 Jun 20248 earlier quartersnormal: $6.6M

Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

Check it at the source: SEC EDGAR quarterly reports.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

7 May 2024confirmed

Confirmed across sources Filings + Financials and Lobbying

NovoCure (NVCR): reported $200K of lobbying spend for the quarter ended 31 Mar 2024, 1.7× the same quarter last year, while it spent $11.8M on capital projects in the quarter ended 31 Mar 2024, 1.9× the same quarter last year. Two unrelated kinds of activity within 14 days.

  • Lobbying: Lobbying spend jump, became public on 22 Apr 2024
  • Financials: Quarterly capital spending jump, became public on 7 May 2024
2022-03-31: $110K2022-06-30: $120K2022-09-30: $120K2022-12-31: $120K2023-03-31: $120K2023-06-30: $180K2023-09-30: $140K2023-12-31: $120K2024-03-31: $200K
The quarter ended 31 Mar 2024 against the 8 quarters before it. this quarterearliernormal: $120K
See the evidence (2 changes)

Lobbying: Lobbying spend jump became public on 22 Apr 2024

NovoCure reported $200K of lobbying spend for the quarter ended 31 Mar 2024, 1.7× the same quarter last year.

This period
$200K (the quarter ended 31 Mar 2024)
Normal quarter (median of 8 earlier)
$120K
Typical spread (median absolute deviation)
$0
How far from its usual level
+4.0
Same quarter last year
$120K
History used
3,743 days
2022-03-31: $110K2022-06-30: $120K2022-09-30: $120K2022-12-31: $120K2023-03-31: $120K2023-06-30: $180K2023-09-30: $140K2023-12-31: $120K2024-03-31: $200K
the quarter ended 31 Mar 20248 earlier quartersnormal: $120K

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least $100K.

Check it at the source: Senate/House lobbying disclosures (LDA).

Financials: Quarterly capital spending jump became public on 7 May 2024

NovoCure spent $11.8M on capital projects in the quarter ended 31 Mar 2024, 1.9× the same quarter last year.

This period
$11.8M (the quarter ended 31 Mar 2024)
Normal quarter (median of 8 earlier)
$6.3M
Typical spread (median absolute deviation)
$616K
How far from its usual level
+5.5
Same quarter last year
$6.1M
History used
3,378 days
2022-03-31: $5.1M2022-06-30: $4.1M2022-09-30: $5.7M2022-12-31: $6.4M2023-03-31: $6.1M2023-06-30: $6.9M2023-09-30: $7.3M2023-12-31: $6.8M2024-03-31: $11.8M
the quarter ended 31 Mar 20248 earlier quartersnormal: $6.3M

Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

Check it at the source: SEC EDGAR quarterly reports.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

Timeline

Changes and notable records, by the date each became public

  1. 9 Sep 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  2. 9 Sep 2026Filings record

    Director or officer change

  3. 5 Jun 2026Filings record

    Director or officer change

  4. 11 Apr 2026Short interest and volume change

    had 9.1M shares sold short in the 31 Mar 2026 report, 1.7× the same report last year.

    Same report last year: 5.4M; its normal report is 5.7M.

    See the evidence
    This period
    9.1M (the 31 Mar 2026 report)
    Normal report (median of 24 earlier)
    5.7M
    Typical spread (median absolute deviation)
    548K
    How far from its usual level
    +4.1
    Same report last year
    5.4M
    History used
    3,014 days
    2025-03-31: 5.4M2025-04-15: 5.1M2025-04-30: 5.4M2025-05-15: 5.4M2025-05-30: 4.6M2025-06-13: 4.9M2025-06-30: 5.2M2025-07-15: 4.9M2025-07-31: 5.2M2025-08-15: 5.5M2025-08-29: 6.0M2025-09-15: 5.9M2025-09-30: 5.7M2025-10-15: 5.2M2025-10-31: 5.7M2025-11-14: 6.0M2025-11-28: 6.8M2025-12-15: 6.9M2025-12-31: 8.3M2026-01-15: 7.4M2026-01-30: 8.0M2026-02-13: 8.9M2026-02-27: 9.1M2026-03-13: 8.5M2026-03-31: 9.1M
    the 31 Mar 2026 report24 earlier reportsnormal: 5.7M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  5. 9 Apr 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  6. 9 Apr 2026Filings record

    Director or officer change

  7. 25 Mar 2026Short interest and volume change

    had 8.5M shares sold short in the 13 Mar 2026 report, 1.6× the same report last year.

    Same report last year: 5.4M; its normal report is 5.6M.

    See the evidence
    This period
    8.5M (the 13 Mar 2026 report)
    Normal report (median of 24 earlier)
    5.6M
    Typical spread (median absolute deviation)
    384K
    How far from its usual level
    +5.1
    Same report last year
    5.4M
    History used
    2,996 days
    2025-03-14: 5.4M2025-03-31: 5.4M2025-04-15: 5.1M2025-04-30: 5.4M2025-05-15: 5.4M2025-05-30: 4.6M2025-06-13: 4.9M2025-06-30: 5.2M2025-07-15: 4.9M2025-07-31: 5.2M2025-08-15: 5.5M2025-08-29: 6.0M2025-09-15: 5.9M2025-09-30: 5.7M2025-10-15: 5.2M2025-10-31: 5.7M2025-11-14: 6.0M2025-11-28: 6.8M2025-12-15: 6.9M2025-12-31: 8.3M2026-01-15: 7.4M2026-01-30: 8.0M2026-02-13: 8.9M2026-02-27: 9.1M2026-03-13: 8.5M
    the 13 Mar 2026 report24 earlier reportsnormal: 5.6M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  8. 11 Mar 2026Short interest and volume change

    had 9.1M shares sold short in the 27 Feb 2026 report, 1.7× the same report last year.

    Same report last year: 5.2M; its normal report is 5.5M.

    See the evidence
    This period
    9.1M (the 27 Feb 2026 report)
    Normal report (median of 24 earlier)
    5.5M
    Typical spread (median absolute deviation)
    375K
    How far from its usual level
    +6.6
    Same report last year
    5.2M
    History used
    2,982 days
    2025-02-28: 5.2M2025-03-14: 5.4M2025-03-31: 5.4M2025-04-15: 5.1M2025-04-30: 5.4M2025-05-15: 5.4M2025-05-30: 4.6M2025-06-13: 4.9M2025-06-30: 5.2M2025-07-15: 4.9M2025-07-31: 5.2M2025-08-15: 5.5M2025-08-29: 6.0M2025-09-15: 5.9M2025-09-30: 5.7M2025-10-15: 5.2M2025-10-31: 5.7M2025-11-14: 6.0M2025-11-28: 6.8M2025-12-15: 6.9M2025-12-31: 8.3M2026-01-15: 7.4M2026-01-30: 8.0M2026-02-13: 8.9M2026-02-27: 9.1M
    the 27 Feb 2026 report24 earlier reportsnormal: 5.5M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  9. 26 Feb 2026Short interest and volume change

    had 8.9M shares sold short in the 13 Feb 2026 report, 1.7× the same report last year.

    Same report last year: 5.2M; its normal report is 5.4M.

    See the evidence
    This period
    8.9M (the 13 Feb 2026 report)
    Normal report (median of 24 earlier)
    5.4M
    Typical spread (median absolute deviation)
    305K
    How far from its usual level
    +6.4
    Same report last year
    5.2M
    History used
    2,968 days
    2025-02-14: 5.2M2025-02-28: 5.2M2025-03-14: 5.4M2025-03-31: 5.4M2025-04-15: 5.1M2025-04-30: 5.4M2025-05-15: 5.4M2025-05-30: 4.6M2025-06-13: 4.9M2025-06-30: 5.2M2025-07-15: 4.9M2025-07-31: 5.2M2025-08-15: 5.5M2025-08-29: 6.0M2025-09-15: 5.9M2025-09-30: 5.7M2025-10-15: 5.2M2025-10-31: 5.7M2025-11-14: 6.0M2025-11-28: 6.8M2025-12-15: 6.9M2025-12-31: 8.3M2026-01-15: 7.4M2026-01-30: 8.0M2026-02-13: 8.9M
    the 13 Feb 2026 report24 earlier reportsnormal: 5.4M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  10. 11 Feb 2026Short interest and volume change

    had 8.0M shares sold short in the 30 Jan 2026 report, 1.6× the same report last year.

    Same report last year: 5.0M; its normal report is 5.4M.

    See the evidence
    This period
    8.0M (the 30 Jan 2026 report)
    Normal report (median of 24 earlier)
    5.4M
    Typical spread (median absolute deviation)
    319K
    How far from its usual level
    +4.7
    Same report last year
    5.0M
    History used
    2,954 days
    2025-01-31: 5.0M2025-02-14: 5.2M2025-02-28: 5.2M2025-03-14: 5.4M2025-03-31: 5.4M2025-04-15: 5.1M2025-04-30: 5.4M2025-05-15: 5.4M2025-05-30: 4.6M2025-06-13: 4.9M2025-06-30: 5.2M2025-07-15: 4.9M2025-07-31: 5.2M2025-08-15: 5.5M2025-08-29: 6.0M2025-09-15: 5.9M2025-09-30: 5.7M2025-10-15: 5.2M2025-10-31: 5.7M2025-11-14: 6.0M2025-11-28: 6.8M2025-12-15: 6.9M2025-12-31: 8.3M2026-01-15: 7.4M2026-01-30: 8.0M
    the 30 Jan 2026 report24 earlier reportsnormal: 5.4M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  11. 28 Jan 2026Short interest and volume change

    had 7.4M shares sold short in the 15 Jan 2026 report, 1.5× the same report last year.

    Same report last year: 4.9M; its normal report is 5.4M.

    See the evidence
    This period
    7.4M (the 15 Jan 2026 report)
    Normal report (median of 24 earlier)
    5.4M
    Typical spread (median absolute deviation)
    331K
    How far from its usual level
    +3.8
    Same report last year
    4.9M
    History used
    2,939 days
    2025-01-15: 4.9M2025-01-31: 5.0M2025-02-14: 5.2M2025-02-28: 5.2M2025-03-14: 5.4M2025-03-31: 5.4M2025-04-15: 5.1M2025-04-30: 5.4M2025-05-15: 5.4M2025-05-30: 4.6M2025-06-13: 4.9M2025-06-30: 5.2M2025-07-15: 4.9M2025-07-31: 5.2M2025-08-15: 5.5M2025-08-29: 6.0M2025-09-15: 5.9M2025-09-30: 5.7M2025-10-15: 5.2M2025-10-31: 5.7M2025-11-14: 6.0M2025-11-28: 6.8M2025-12-15: 6.9M2025-12-31: 8.3M2026-01-15: 7.4M
    the 15 Jan 2026 report24 earlier reportsnormal: 5.4M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  12. 21 Jan 2026several at once

    lobbying on a new issue, while it had 9.1M shares sold short in the 27 Feb 2026 report, 1.7× the same report last year. Two unrelated kinds of activity within 91 days.

    See the evidence (8 changes)

    Short interest and volume: Short interest spike became public on 13 Jan 2026

    NovoCure had 8.3M shares sold short in the 31 Dec 2025 report, 1.5× the same report last year.

    This period
    8.3M (the 31 Dec 2025 report)
    Normal report (median of 24 earlier)
    5.4M
    Typical spread (median absolute deviation)
    288K
    How far from its usual level
    +5.4
    Same report last year
    5.4M
    History used
    2,924 days
    2024-12-31: 5.4M2025-01-15: 4.9M2025-01-31: 5.0M2025-02-14: 5.2M2025-02-28: 5.2M2025-03-14: 5.4M2025-03-31: 5.4M2025-04-15: 5.1M2025-04-30: 5.4M2025-05-15: 5.4M2025-05-30: 4.6M2025-06-13: 4.9M2025-06-30: 5.2M2025-07-15: 4.9M2025-07-31: 5.2M2025-08-15: 5.5M2025-08-29: 6.0M2025-09-15: 5.9M2025-09-30: 5.7M2025-10-15: 5.2M2025-10-31: 5.7M2025-11-14: 6.0M2025-11-28: 6.8M2025-12-15: 6.9M2025-12-31: 8.3M
    the 31 Dec 2025 report24 earlier reportsnormal: 5.4M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Lobbying: Lobbying on a new issue became public on 21 Jan 2026

    NovoCure lobbying on a new issue.

    New
    ['PHA', 'TAR', 'TRD']
    Rule
    only points whose every posting (and value revision) is at or before as_of
    Field
    issue_codes
    Metric
    lobbying.filings_count
    Point id
    4689088

    Short interest and volume: Short interest spike became public on 28 Jan 2026

    NovoCure had 7.4M shares sold short in the 15 Jan 2026 report, 1.5× the same report last year.

    This period
    7.4M (the 15 Jan 2026 report)
    Normal report (median of 24 earlier)
    5.4M
    Typical spread (median absolute deviation)
    331K
    How far from its usual level
    +3.8
    Same report last year
    4.9M
    History used
    2,939 days
    2025-01-15: 4.9M2025-01-31: 5.0M2025-02-14: 5.2M2025-02-28: 5.2M2025-03-14: 5.4M2025-03-31: 5.4M2025-04-15: 5.1M2025-04-30: 5.4M2025-05-15: 5.4M2025-05-30: 4.6M2025-06-13: 4.9M2025-06-30: 5.2M2025-07-15: 4.9M2025-07-31: 5.2M2025-08-15: 5.5M2025-08-29: 6.0M2025-09-15: 5.9M2025-09-30: 5.7M2025-10-15: 5.2M2025-10-31: 5.7M2025-11-14: 6.0M2025-11-28: 6.8M2025-12-15: 6.9M2025-12-31: 8.3M2026-01-15: 7.4M
    the 15 Jan 2026 report24 earlier reportsnormal: 5.4M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 11 Feb 2026

    NovoCure had 8.0M shares sold short in the 30 Jan 2026 report, 1.6× the same report last year.

    This period
    8.0M (the 30 Jan 2026 report)
    Normal report (median of 24 earlier)
    5.4M
    Typical spread (median absolute deviation)
    319K
    How far from its usual level
    +4.7
    Same report last year
    5.0M
    History used
    2,954 days
    2025-01-31: 5.0M2025-02-14: 5.2M2025-02-28: 5.2M2025-03-14: 5.4M2025-03-31: 5.4M2025-04-15: 5.1M2025-04-30: 5.4M2025-05-15: 5.4M2025-05-30: 4.6M2025-06-13: 4.9M2025-06-30: 5.2M2025-07-15: 4.9M2025-07-31: 5.2M2025-08-15: 5.5M2025-08-29: 6.0M2025-09-15: 5.9M2025-09-30: 5.7M2025-10-15: 5.2M2025-10-31: 5.7M2025-11-14: 6.0M2025-11-28: 6.8M2025-12-15: 6.9M2025-12-31: 8.3M2026-01-15: 7.4M2026-01-30: 8.0M
    the 30 Jan 2026 report24 earlier reportsnormal: 5.4M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 26 Feb 2026

    NovoCure had 8.9M shares sold short in the 13 Feb 2026 report, 1.7× the same report last year.

    This period
    8.9M (the 13 Feb 2026 report)
    Normal report (median of 24 earlier)
    5.4M
    Typical spread (median absolute deviation)
    305K
    How far from its usual level
    +6.4
    Same report last year
    5.2M
    History used
    2,968 days
    2025-02-14: 5.2M2025-02-28: 5.2M2025-03-14: 5.4M2025-03-31: 5.4M2025-04-15: 5.1M2025-04-30: 5.4M2025-05-15: 5.4M2025-05-30: 4.6M2025-06-13: 4.9M2025-06-30: 5.2M2025-07-15: 4.9M2025-07-31: 5.2M2025-08-15: 5.5M2025-08-29: 6.0M2025-09-15: 5.9M2025-09-30: 5.7M2025-10-15: 5.2M2025-10-31: 5.7M2025-11-14: 6.0M2025-11-28: 6.8M2025-12-15: 6.9M2025-12-31: 8.3M2026-01-15: 7.4M2026-01-30: 8.0M2026-02-13: 8.9M
    the 13 Feb 2026 report24 earlier reportsnormal: 5.4M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 11 Mar 2026

    NovoCure had 9.1M shares sold short in the 27 Feb 2026 report, 1.7× the same report last year.

    This period
    9.1M (the 27 Feb 2026 report)
    Normal report (median of 24 earlier)
    5.5M
    Typical spread (median absolute deviation)
    375K
    How far from its usual level
    +6.6
    Same report last year
    5.2M
    History used
    2,982 days
    2025-02-28: 5.2M2025-03-14: 5.4M2025-03-31: 5.4M2025-04-15: 5.1M2025-04-30: 5.4M2025-05-15: 5.4M2025-05-30: 4.6M2025-06-13: 4.9M2025-06-30: 5.2M2025-07-15: 4.9M2025-07-31: 5.2M2025-08-15: 5.5M2025-08-29: 6.0M2025-09-15: 5.9M2025-09-30: 5.7M2025-10-15: 5.2M2025-10-31: 5.7M2025-11-14: 6.0M2025-11-28: 6.8M2025-12-15: 6.9M2025-12-31: 8.3M2026-01-15: 7.4M2026-01-30: 8.0M2026-02-13: 8.9M2026-02-27: 9.1M
    the 27 Feb 2026 report24 earlier reportsnormal: 5.5M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 25 Mar 2026

    NovoCure had 8.5M shares sold short in the 13 Mar 2026 report, 1.6× the same report last year.

    This period
    8.5M (the 13 Mar 2026 report)
    Normal report (median of 24 earlier)
    5.6M
    Typical spread (median absolute deviation)
    384K
    How far from its usual level
    +5.1
    Same report last year
    5.4M
    History used
    2,996 days
    2025-03-14: 5.4M2025-03-31: 5.4M2025-04-15: 5.1M2025-04-30: 5.4M2025-05-15: 5.4M2025-05-30: 4.6M2025-06-13: 4.9M2025-06-30: 5.2M2025-07-15: 4.9M2025-07-31: 5.2M2025-08-15: 5.5M2025-08-29: 6.0M2025-09-15: 5.9M2025-09-30: 5.7M2025-10-15: 5.2M2025-10-31: 5.7M2025-11-14: 6.0M2025-11-28: 6.8M2025-12-15: 6.9M2025-12-31: 8.3M2026-01-15: 7.4M2026-01-30: 8.0M2026-02-13: 8.9M2026-02-27: 9.1M2026-03-13: 8.5M
    the 13 Mar 2026 report24 earlier reportsnormal: 5.6M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 11 Apr 2026

    NovoCure had 9.1M shares sold short in the 31 Mar 2026 report, 1.7× the same report last year.

    This period
    9.1M (the 31 Mar 2026 report)
    Normal report (median of 24 earlier)
    5.7M
    Typical spread (median absolute deviation)
    548K
    How far from its usual level
    +4.1
    Same report last year
    5.4M
    History used
    3,014 days
    2025-03-31: 5.4M2025-04-15: 5.1M2025-04-30: 5.4M2025-05-15: 5.4M2025-05-30: 4.6M2025-06-13: 4.9M2025-06-30: 5.2M2025-07-15: 4.9M2025-07-31: 5.2M2025-08-15: 5.5M2025-08-29: 6.0M2025-09-15: 5.9M2025-09-30: 5.7M2025-10-15: 5.2M2025-10-31: 5.7M2025-11-14: 6.0M2025-11-28: 6.8M2025-12-15: 6.9M2025-12-31: 8.3M2026-01-15: 7.4M2026-01-30: 8.0M2026-02-13: 8.9M2026-02-27: 9.1M2026-03-13: 8.5M2026-03-31: 9.1M
    the 31 Mar 2026 report24 earlier reportsnormal: 5.7M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

  13. 21 Jan 2026Lobbying change

    lobbying on a new issue.

    See the evidence
    New
    ['PHA', 'TAR', 'TRD']
    Rule
    only points whose every posting (and value revision) is at or before as_of
    Field
    issue_codes
    Metric
    lobbying.filings_count
    Point id
    4689088
  14. 21 Jan 2026Lobbying record

    NOVOCURE: new lobbying registration (MAYER BROWN LLP) (dated 5 Dec 2025)

  15. 13 Jan 2026Short interest and volume change

    had 8.3M shares sold short in the 31 Dec 2025 report, 1.5× the same report last year.

    Same report last year: 5.4M; its normal report is 5.4M.

    See the evidence
    This period
    8.3M (the 31 Dec 2025 report)
    Normal report (median of 24 earlier)
    5.4M
    Typical spread (median absolute deviation)
    288K
    How far from its usual level
    +5.4
    Same report last year
    5.4M
    History used
    2,924 days
    2024-12-31: 5.4M2025-01-15: 4.9M2025-01-31: 5.0M2025-02-14: 5.2M2025-02-28: 5.2M2025-03-14: 5.4M2025-03-31: 5.4M2025-04-15: 5.1M2025-04-30: 5.4M2025-05-15: 5.4M2025-05-30: 4.6M2025-06-13: 4.9M2025-06-30: 5.2M2025-07-15: 4.9M2025-07-31: 5.2M2025-08-15: 5.5M2025-08-29: 6.0M2025-09-15: 5.9M2025-09-30: 5.7M2025-10-15: 5.2M2025-10-31: 5.7M2025-11-14: 6.0M2025-11-28: 6.8M2025-12-15: 6.9M2025-12-31: 8.3M
    the 31 Dec 2025 report24 earlier reportsnormal: 5.4M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  16. 1 Dec 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  17. 1 Dec 2025Filings record

    Director or officer change

  18. 20 Nov 2025Lobbying record

    NOVOCURE INC.: new lobbying registration (WILLIAMS AND JENSEN, PLLC) (dated 8 Oct 2025)

  19. 9 Sep 2025Insiders record

    Cordova Ashley (Chief Executive Officer) bought 81,550 shares of NVCR ($996,541) (dated 8 Sep 2025)

  20. 31 Jul 2025Insiders record

    Brackmann Christoph (Chief Financial Officer) bought 20,000 shares of NVCR ($231,800) (dated 30 Jul 2025)

  21. 6 Jun 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  22. 6 Jun 2025Filings record

    Director or officer change

  23. 30 Oct 2024Filings record

    Director or officer change

  24. 3 Sep 2024Filings record

    Director or officer change

  25. 30 Jul 2024several at once

    reported $220K of lobbying spend for the quarter ended 30 Jun 2024, 1.2× the same quarter last year, while it spent $11.4M on capital projects in the quarter ended 30 Jun 2024, 1.7× the same quarter last year. Two unrelated kinds of activity within 7 days.

    See the evidence (2 changes)

    Lobbying: Lobbying spend jump became public on 22 Jul 2024

    NovoCure reported $220K of lobbying spend for the quarter ended 30 Jun 2024, 1.2× the same quarter last year.

    This period
    $220K (the quarter ended 30 Jun 2024)
    Normal quarter (median of 8 earlier)
    $120K
    Typical spread (median absolute deviation)
    $0
    How far from its usual level
    +5.0
    Same quarter last year
    $180K
    History used
    3,834 days
    2022-06-30: $120K2022-09-30: $120K2022-12-31: $120K2023-03-31: $120K2023-06-30: $180K2023-09-30: $140K2023-12-31: $120K2024-03-31: $200K2024-06-30: $220K
    the quarter ended 30 Jun 20248 earlier quartersnormal: $120K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least $100K.

    Check it at the source: Senate/House lobbying disclosures (LDA).

    Financials: Quarterly capital spending jump became public on 30 Jul 2024

    NovoCure spent $11.4M on capital projects in the quarter ended 30 Jun 2024, 1.7× the same quarter last year.

    This period
    $11.4M (the quarter ended 30 Jun 2024)
    Normal quarter (median of 8 earlier)
    $6.6M
    Typical spread (median absolute deviation)
    $582K
    How far from its usual level
    +4.8
    Same quarter last year
    $6.9M
    History used
    3,469 days
    2022-06-30: $4.1M2022-09-30: $5.7M2022-12-31: $6.4M2023-03-31: $6.1M2023-06-30: $6.9M2023-09-30: $7.3M2023-12-31: $6.8M2024-03-31: $11.8M2024-06-30: $11.4M
    the quarter ended 30 Jun 20248 earlier quartersnormal: $6.6M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

    Check it at the source: SEC EDGAR quarterly reports.

    Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

  26. 30 Jul 2024Financials change

    spent $11.4M on capital projects in the quarter ended 30 Jun 2024, 1.7× the same quarter last year.

    Same quarter last year: $6.9M; its normal quarter is $6.6M.

    See the evidence
    This period
    $11.4M (the quarter ended 30 Jun 2024)
    Normal quarter (median of 8 earlier)
    $6.6M
    Typical spread (median absolute deviation)
    $582K
    How far from its usual level
    +4.8
    Same quarter last year
    $6.9M
    History used
    3,469 days
    2022-06-30: $4.1M2022-09-30: $5.7M2022-12-31: $6.4M2023-03-31: $6.1M2023-06-30: $6.9M2023-09-30: $7.3M2023-12-31: $6.8M2024-03-31: $11.8M2024-06-30: $11.4M
    the quarter ended 30 Jun 20248 earlier quartersnormal: $6.6M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  27. 22 Jul 2024Lobbying change

    reported $220K of lobbying spend for the quarter ended 30 Jun 2024, 1.2× the same quarter last year.

    Same quarter last year: $180K; its normal quarter is $120K.

    See the evidence
    This period
    $220K (the quarter ended 30 Jun 2024)
    Normal quarter (median of 8 earlier)
    $120K
    Typical spread (median absolute deviation)
    $0
    How far from its usual level
    +5.0
    Same quarter last year
    $180K
    History used
    3,834 days
    2022-06-30: $120K2022-09-30: $120K2022-12-31: $120K2023-03-31: $120K2023-06-30: $180K2023-09-30: $140K2023-12-31: $120K2024-03-31: $200K2024-06-30: $220K
    the quarter ended 30 Jun 20248 earlier quartersnormal: $120K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least $100K.

    Check it at the source: Senate/House lobbying disclosures (LDA).

  28. 10 Jun 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  29. 10 Jun 2024Filings record

    Director or officer change

  30. 7 May 2024several at once

    reported $200K of lobbying spend for the quarter ended 31 Mar 2024, 1.7× the same quarter last year, while it spent $11.8M on capital projects in the quarter ended 31 Mar 2024, 1.9× the same quarter last year. Two unrelated kinds of activity within 14 days.

    See the evidence (2 changes)

    Lobbying: Lobbying spend jump became public on 22 Apr 2024

    NovoCure reported $200K of lobbying spend for the quarter ended 31 Mar 2024, 1.7× the same quarter last year.

    This period
    $200K (the quarter ended 31 Mar 2024)
    Normal quarter (median of 8 earlier)
    $120K
    Typical spread (median absolute deviation)
    $0
    How far from its usual level
    +4.0
    Same quarter last year
    $120K
    History used
    3,743 days
    2022-03-31: $110K2022-06-30: $120K2022-09-30: $120K2022-12-31: $120K2023-03-31: $120K2023-06-30: $180K2023-09-30: $140K2023-12-31: $120K2024-03-31: $200K
    the quarter ended 31 Mar 20248 earlier quartersnormal: $120K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least $100K.

    Check it at the source: Senate/House lobbying disclosures (LDA).

    Financials: Quarterly capital spending jump became public on 7 May 2024

    NovoCure spent $11.8M on capital projects in the quarter ended 31 Mar 2024, 1.9× the same quarter last year.

    This period
    $11.8M (the quarter ended 31 Mar 2024)
    Normal quarter (median of 8 earlier)
    $6.3M
    Typical spread (median absolute deviation)
    $616K
    How far from its usual level
    +5.5
    Same quarter last year
    $6.1M
    History used
    3,378 days
    2022-03-31: $5.1M2022-06-30: $4.1M2022-09-30: $5.7M2022-12-31: $6.4M2023-03-31: $6.1M2023-06-30: $6.9M2023-09-30: $7.3M2023-12-31: $6.8M2024-03-31: $11.8M
    the quarter ended 31 Mar 20248 earlier quartersnormal: $6.3M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

    Check it at the source: SEC EDGAR quarterly reports.

    Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

  31. 7 May 2024Financials change

    spent $11.8M on capital projects in the quarter ended 31 Mar 2024, 1.9× the same quarter last year.

    Same quarter last year: $6.1M; its normal quarter is $6.3M.

    See the evidence
    This period
    $11.8M (the quarter ended 31 Mar 2024)
    Normal quarter (median of 8 earlier)
    $6.3M
    Typical spread (median absolute deviation)
    $616K
    How far from its usual level
    +5.5
    Same quarter last year
    $6.1M
    History used
    3,378 days
    2022-03-31: $5.1M2022-06-30: $4.1M2022-09-30: $5.7M2022-12-31: $6.4M2023-03-31: $6.1M2023-06-30: $6.9M2023-09-30: $7.3M2023-12-31: $6.8M2024-03-31: $11.8M
    the quarter ended 31 Mar 20248 earlier quartersnormal: $6.3M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  32. 22 Apr 2024Lobbying change

    reported $200K of lobbying spend for the quarter ended 31 Mar 2024, 1.7× the same quarter last year.

    Same quarter last year: $120K; its normal quarter is $120K.

    See the evidence
    This period
    $200K (the quarter ended 31 Mar 2024)
    Normal quarter (median of 8 earlier)
    $120K
    Typical spread (median absolute deviation)
    $0
    How far from its usual level
    +4.0
    Same quarter last year
    $120K
    History used
    3,743 days
    2022-03-31: $110K2022-06-30: $120K2022-09-30: $120K2022-12-31: $120K2023-03-31: $120K2023-06-30: $180K2023-09-30: $140K2023-12-31: $120K2024-03-31: $200K
    the quarter ended 31 Mar 20248 earlier quartersnormal: $120K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least $100K.

    Check it at the source: Senate/House lobbying disclosures (LDA).

  33. 4 Jan 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  34. 4 Jan 2024Filings record

    Director or officer change

  35. 8 Jun 2023Filings record

    Director or officer change

  36. 29 Mar 2023Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  37. 29 Mar 2023Filings record

    Director or officer change

  38. 21 Jan 2023Lobbying change

    lobbying on a new issue.

    See the evidence
    New
    ['TRA']
    Rule
    only points whose every posting (and value revision) is at or before as_of
    Field
    issue_codes
    Metric
    lobbying.filings_count
    Point id
    12626405
  39. 10 Jun 2022Filings record

    Director or officer change

  40. 25 May 2022Short interest and volume change

    had 8.2M shares sold short in the 13 May 2022 report, 1.6× the same report last year.

    Same report last year: 5.0M; its normal report is 5.4M.

    See the evidence
    This period
    8.2M (the 13 May 2022 report)
    Normal report (median of 24 earlier)
    5.4M
    Typical spread (median absolute deviation)
    362K
    How far from its usual level
    +5.0
    Same report last year
    5.0M
    History used
    1,596 days
    2021-04-30: 4.9M2021-05-14: 5.0M2021-05-28: 5.1M2021-06-15: 5.4M2021-06-30: 5.1M2021-07-15: 5.1M2021-07-30: 5.2M2021-08-13: 5.4M2021-08-31: 5.4M2021-09-15: 5.4M2021-09-30: 5.4M2021-10-15: 5.3M2021-10-29: 5.3M2021-11-15: 5.7M2021-11-30: 6.1M2021-12-15: 5.8M2022-01-14: 6.3M2022-01-31: 6.6M2022-02-15: 7.2M2022-02-28: 7.2M2022-03-15: 7.3M2022-03-31: 7.5M2022-04-14: 7.4M2022-04-29: 7.8M2022-05-13: 8.2M
    the 13 May 2022 report24 earlier reportsnormal: 5.4M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

Showing the newest 40 of 100 entries; narrow the window or the kind of data to see older ones.

Not listed: 537 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001645113
Ticker
NVCR
Domain
novocure.com
Employer name
Novocure, Inc. (1 unverified)
Lobbying client
novocure
Name
Novocure Austria GmbH, Novocure Belgium S.r.l, Novocure Canada, Inc, Novocure Capital S.à.r.l and 13 more
Uei
P3S3GK3DTUA8, WC4JMKBKHCJ8
  • DOL H-1B labor condition applications and PERM certifications21 data points4 Sep 2023 to 27 Apr 2026
  • Federal lobbying disclosures (LDA)10 records, 156 data points11 Dec 2013 to 30 Sep 2026
  • SEC Form 13F institutional holdings1 record, 396 data points31 Dec 2015 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)161 records29 Feb 2016 to 29 Oct 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)898 data points31 Dec 2012 to 23 Oct 2026
  • SEC Form 4 insider transactions422 records, 932 data points4 Mar 2016 to 12 Nov 2026
  • FINRA short interest (twice monthly)624 data points29 Dec 2017 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)4178 data points1 Aug 2018 to 20 Nov 2026
  • USASpending.gov federal awards2754 data points21 Feb 2019 to 20 Nov 2026